MAPT and Alzheimer disease: In contrast, the IWG and NIA‐AA criteria include functional or structural imaging biomarkers, fluid and imaging markers for Aβ and tau, and genetic markers to support the AD diagnosis and confirm the presence of AD pathology.1, 21, 23, 24, 30